Role of Human Serum Albumin in the Prevention and Treatment of Alzheimer’s Disease

Alzheimer’s disease (AD) was and remains the main cause of the development of dementia in older patients. This neurodegenerative disease is characterized by a progressive course and belongs to a group of socially significant diseases. There are several hypotheses for the development of AD: the tau hypothesis, the amyloid hypothesis, the cholinergic hypothesis, the hypotheses of oxidative stress and inflammation. The absence of a generally accepted understanding of the etiology and pathogenesis of AD prevents the development of new efficient methods for its treatment and prevention. In clinical practice, cholinesterase inhibitors that alleviate the symptoms of the disease but do not affect its course are widely used. In 2021, a drug for pathogenetic therapy of AD (aducanumab), which contributes to a decrease in the content of amyloid-β peptide (Aβ) in the brain of patients, was for the first time approved. The effect on human serum albumin (HSA), which carries 90